Evidence map›Paper›PMID 34477946›Full record

ArticleJournal of cancer research and clinical oncology2021

Selective induction of rapid cytotoxic effect in glioblastoma cells by oscillating magnetic fields.

Santosh A Helekar, Shashank Hambarde, Omkar B Ijare, Kumar Pichumani, David S Baskin, Martyn A Sharpe

Open access · greenAbstract read
In one paragraph

Article in Journal of cancer research and clinical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.7field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Neuromodulation in Neuro-Oncology: A Scoping Review.Journal of personalized medicine · 2026
    Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Santosh A Helekar *Kenneth R. Peak Center for Brain and Pituitary Tumor Treatment and Research, Houston Methodist Hospital, 6445 Main St., Floor 24, Houston, TX, 77030, USA. sahelekar@houstonmethodist.org.ORCID http://orcid.org/0000-0002-9264-0966
Shashank Hambarde *Kenneth R. Peak Center for Brain and Pituitary Tumor Treatment and Research, Houston Methodist Hospital, 6445 Main St., Floor 24, Houston, TX, 77030, USA.
Omkar B IjareKenneth R. Peak Center for Brain and Pituitary Tumor Treatment and Research, Houston Methodist Hospital, 6445 Main St., Floor 24, Houston, TX, 77030, USA.
Kumar PichumaniKenneth R. Peak Center for Brain and Pituitary Tumor Treatment and Research, Houston Methodist Hospital, 6445 Main St., Floor 24, Houston, TX, 77030, USA.
David S BaskinKenneth R. Peak Center for Brain and Pituitary Tumor Treatment and Research, Houston Methodist Hospital, 6445 Main St., Floor 24, Houston, TX, 77030, USA.
Martyn A SharpeKenneth R. Peak Center for Brain and Pituitary Tumor Treatment and Research, Houston Methodist Hospital, 6445 Main St., Floor 24, Houston, TX, 77030, USA.
Houston Methodist · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe mechanisms underlying anticancer effects of electromagnetic fields are poorly understood. An alternating electric field-generating therapeutic device called Optune™ device has been approved for the treatment of glioblastoma (GBM). We have developed a new device that generates oscillating magnetic fields (OMF) by rapid rotation of strong permanent magnets in specially designed patterns of frequency and timing and have used it to treat an end-stage recurrent GBM patient under an expanded access/compassionate use treatment protocol. Here, we ask whether OMF causes selective cytotoxic effects in GBM and whether it is through generation of reactive oxygen species (ROS).

methodsWe stimulated patient derived GBM cells, lung cancer cells, normal human cortical neurons, astrocytes, and bronchial epithelial cells using OMF generators (oncoscillators) of our Oncomagnetic Device and compared the results to those obtained under unstimulated or sham-stimulated control conditions. Quantitative fluorescence microscopy was used to assess cell morphology, viability, and ROS production mechanisms.

resultsWe find that OMF induces highly selective cell death of patient derived GBM cells associated with activation of caspase 3, while leaving normal tissue cells undamaged. The cytotoxic effect of OMF is also seen in pulmonary cancer cells. The underlying mechanism is a marked increase in ROS in the mitochondria, possibly in part through perturbation of the electron flow in the respiratory chain.

conclusionRotating magnetic fields produced by a new noninvasive device selectively kill cultured human glioblastoma and non-small cell lung cancer cells by raising intracellular reactive oxygen species, but not normal human tissue cells.

Indexed as

Brain NeoplasmsGlioblastomaCell DeathHumansMagnetic Field TherapyTumor Cells, CulturedBrain tumorCell cultureNoninvasive treatmentOncomagnetic deviceReactive oxygen species

Identifiers

PMID34477946
PMCPMC11801958
OpenAlexW3197930904

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.